Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Upstate Carolina CCOP
mi
from
Spartanburg, SC
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Upstate Carolina CCOP
mi
from
Spartanburg, SC
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Spartanburg Regional Health Service District
mi
from
Spartanburg, SC
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Spartanburg Regional Health Service District
mi
from
Spartanburg, SC
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
CCOP Holston Valley Medical Center
mi
from
Kingsport, TN
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
CCOP Holston Valley Medical Center
mi
from
Kingsport, TN
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Thompson Cancer Survival Center
mi
from
Knoxville, TN
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Thompson Cancer Survival Center
mi
from
Knoxville, TN
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Danville Regional Medical Center
mi
from
Danville, VA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Danville Regional Medical Center
mi
from
Danville, VA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County
mi
from
Martinsville, VA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County
mi
from
Martinsville, VA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
St. Joseph's Hospital
mi
from
Ann Arbor, MI
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
St. Joseph's Hospital
mi
from
Ann Arbor, MI
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Olympic Hematology and Oncology
mi
from
Bremerton, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Olympic Hematology and Oncology
mi
from
Bremerton, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Skagit Valley Hospital Cancer Care Center
mi
from
Mount Vernon, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Skagit Valley Hospital Cancer Care Center
mi
from
Mount Vernon, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Harrison Poulsbo Hematology and Onocology
mi
from
Poulsbo, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Harrison Poulsbo Hematology and Onocology
mi
from
Poulsbo, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
University of Washington; UW Medical Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Minor and James Medical, PLLC
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Minor and James Medical, PLLC
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Group Health Capitol Hill Campus
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Group Health Capitol Hill Campus
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Polyclinic First Hill
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Polyclinic First Hill
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Swedish Cancer Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Swedish Cancer Center
mi
from
Seattle, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Evergreen Hematology & Oncology
mi
from
Spokane, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Evergreen Hematology & Oncology
mi
from
Spokane, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
North Star Lodge
mi
from
Yakima, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
North Star Lodge
mi
from
Yakima, WA
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Rocky Mountain Oncology
mi
from
Casper, WY
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Rocky Mountain Oncology
mi
from
Casper, WY
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Welch Cancer Center
mi
from
Sheridan, WY
RO4929097 in Treating Patients With Stage IV Melanoma
Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
mi
from
Sheridan, WY
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma
Status: Archived
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
John Wayne Cancer Institute
mi
from
Santa Monica, CA
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Washington County Hospital
mi
from
Hagerstown, MD
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Updated: 1/1/1970
Washington County Hospital
mi
from
Hagerstown, MD
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
New York Oncology Hematology PC-Albany
mi
from
Albany, NY
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Updated: 1/1/1970
New York Oncology Hematology PC-Albany
mi
from
Albany, NY
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Updated: 1/1/1970
Cancer Centers of the Carolinas - Faris Road
mi
from
Greenville, SC
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Virginia Oncology Assoc.
mi
from
Norfolk, VA
E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.
Status: Archived
Updated: 1/1/1970
Virginia Oncology Assoc.
mi
from
Norfolk, VA
An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma
An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated
Status: Archived
ImClone Investigational Site
mi
from
Burlington, MA
An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma
An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated
Status: Archived
Updated: 1/1/1970
ImClone Investigational Site
mi
from
Burlington, MA
An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma
An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma
An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.
Status: Archived
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
Phase II Trial of mTOR Inhibitor Temsirolimus (CCI-779) Combined With MEK Inhibitor AZD 6244 in Treatment-naïve Patients With BRAF Mutant Stage IV Melanoma
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
Phase II Trial of mTOR Inhibitor Temsirolimus (CCI-779) Combined With MEK Inhibitor AZD 6244 in Treatment-naïve Patients With BRAF Mutant Stage IV Melanoma
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Erlotinib Hydrochloride and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Erlotinib Hydrochloride and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
A Pilot Trial to Evaluate the Molecular Effects of RO4929097 as Neoadjuvant Therapy for Resectable Stage IIIB, IIIC or IV Melanoma
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
A Pilot Trial to Evaluate the Molecular Effects of RO4929097 as Neoadjuvant Therapy for Resectable Stage IIIB, IIIC or IV Melanoma
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Archived
Jedd D. Wolchok, Md,Phd
mi
from
New York, NY
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Archived
Updated: 1/1/1970
Jedd D. Wolchok, Md,Phd
mi
from
New York, NY
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Pfizer Investigational Site
mi
from
Alabaster, AL
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Alabaster, AL
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Pfizer Investigational Site
mi
from
Albuquerque, NM
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Albuquerque, NM
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Pfizer Investigational Site
mi
from
Aberdeen, SD
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Aberdeen, SD
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
CP-690-550 Ointment For Chronic Plaque Psoriasis
A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease
Continuing Treatment for Children and Adults in the Center for Cancer Research
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease
Continuing Treatment for Children and Adults in the Center for Cancer Research
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Treatment and Natural History of Acromegaly
Acromegaly Treatment and Natural History
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Treatment and Natural History of Acromegaly
Acromegaly Treatment and Natural History
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Sharp Hospital
mi
from
San Diego, CA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Sharp Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials